Catalyst Pharmaceutical Partners, Inc. Updates on Its Development Activities for Firdapse™
Published: Oct 29, 2013
CORAL GABLES, Fla., Oct. 29, 2013 (GLOBE NEWSWIRE) -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX), a specialty pharmaceutical company focused on developing safe and effective approved medicines targeting orphan neuromuscular and neurological diseases, provided an update on the status of its development activities for its lead product candidate, Firdapse™, which is being evaluated in a pivotal Phase 3 clinical trial for the treatment of Lambert-Eaton Myasthenic Syndrome (LEMS).
Help employers find you! Check out all the jobs and post your resume.